Efficacy of Aficamten vs. Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

Aficamten vs Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pretrial Treatment in MAPLE-HCM

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy

Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive Hypertrophic Cardiomyopathy: Results From FOREST-HCM

Efficacy and Safety of Aficamten in Obstructive Hypertrophic Cardiomyopathy Patients Eligible for Septal Reduction Therapy: A FOREST-HCM Analysis

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: The MAPLE-HCM Randomized Clinical Trial

Serum Magnesium and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction: Insights From the GALACTIC-HF Trial